恆瑞醫藥(01276.HK)與GSK達成獨家授權合作 潛在里程碑金額達120億美元
恆瑞醫藥(01276.HK)宣佈與葛蘭素史克(GSK)簽署戰略合作協議,授予其慢性阻塞性肺病(COPD)創新藥PDE3/4抑制劑HRS-9821在中國大陸、香港、澳門及臺灣以外地區的全球獨家權利,以及最多11個腫瘤、呼吸及自免領域早期項目的選擇權。
根據協議,恆瑞將獲得5億美元首付款,若所有項目開發成功並實現商業化里程碑,潛在總金額可達約120億美元,另可獲得梯度銷售分成。
恆瑞醫藥表示,HRS-9821作爲潛在同類最佳藥物,在早期臨牀和臨牀前研究中已顯示出強效的PDE3和PDE4抑制作用,從而增強支氣管擴張和抗炎作用,適合開發便捷的乾粉吸入器(DPI)製劑。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.